-
公开(公告)号：US20180344488A1
公开(公告)日：2018-12-06
申请号：US16052450
申请日：2018-08-01
Inventor： Muthu WIJESUNDARA , Wei Carrigan
IPC: A61F2/54 , F15B15/10 , B32B3/28 , A61F2/68 , A61F2/78 , A61G7/057 , B25J15/00 , B32B3/26 , B32B27/08 , B32B7/08 , A42B3/12 , A61F2/50 , A61F2/74
CPC classification number: A61F2/54 , A42B3/122 , A61F2/68 , A61F2/78 , A61F2002/5012 , A61F2002/745 , A61G7/05776 , B25J15/0023 , B32B3/266 , B32B3/28 , B32B7/08 , B32B27/08 , B32B2307/51 , B32B2307/546 , B32B2307/732 , B32B2535/00 , F15B15/10
Abstract: This disclosure includes bubble actuator arrays and methods for making and using the same. Some bubble actuator arrays include a first flexible layer having a substantially flat first portion and a plurality of second portions that protrude away from the first portion to define chambers, a flexible second layer sealed to the first layer to define a plurality of cells in the chambers and between the layers, and where the array can be coupled to a fluid source such that the internal pressures of the cells can be varied. Some of the present methods include adjusting with a processor and fluid source the pressure in the cells of an array. Others of the present methods include placing sacrificial material into chambers of a molded first layer such that a plurality of cells is formed when a second layer is molded coincident to the first and the sacrificial material is removed.
-
172.发明申请公开(公告)号：US20180320140A1
公开(公告)日：2018-11-08
申请号：US15773520
申请日：2016-11-04
Inventor： Travis BLOCK , Milos MARINKOVIC , Xiao-dong CHEN
IPC: C12N5/0775 , A61K35/28
CPC classification number: C12N5/0663 , A61K35/28 , C12N5/00 , C12N2533/90
Abstract: Methods of, treatments using, and devices for restoring the regenerative capability for mesenchymal stem cells and isolating and expanding a small subpopulation of less defective mesenchymal stem cells from the bone marrow stromal cells of people with decreased quality and/or quantity of mesenchymal stem cells, such as elderly people.
-
173.发明申请公开(公告)号：US20180271069A1
公开(公告)日：2018-09-27
申请号：US15914728
申请日：2018-03-07
Inventor： Yi-Li MIN , Rhonda BASSEL-DUBY , Eric OLSON
IPC: A01K67/027 , C12N9/22 , C12N9/96 , C12N15/11 , A61K38/46 , A61K31/7105 , A61P21/00
Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, a “humanized” mouse model is provided that can be used to test a variety of DMD exon skipping strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 44 deletion via CRISPR-mediated exon skipping in the humanized mouse model, in patient-derived iPS cells and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.
-
公开(公告)号：US10076562B2
公开(公告)日：2018-09-18
申请号：US15490261
申请日：2017-04-18
Inventor： Ashok K. Chopra , Vladimir L. Motin , Eric Rothe
CPC classification number: A61K39/0291 , A61K39/025 , A61K2039/53 , A61K2039/543 , A61K2039/545 , A61K2039/70 , C12N2710/10043 , Y02A50/407
Abstract: Provided herein are methods for using compositions that include a fusion protein having a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. In one embodiment the composition is used to confer immunity to plague, such as pneumonic plague, caused by Yersinia pestis. In one embodiment, the composition is administered to a mucosal surface, such as by an intranasal route. In one embodiment, the administration to a mucosal surface includes a vector that has a polynucleotide encoding a fusion protein, where the fusion protein includes a YscF protein domain, a mature F1 protein domain, and a LcrV protein domain. The administration is followed by a second administration by a different route, such as an intramuscular route. The second administration includes a fusion protein having the same three domains, and in one embodiment the fusion protein is the same one administered to a mucosal surface.
-
公开(公告)号：US20180258162A1
公开(公告)日：2018-09-13
申请号：US15986382
申请日：2018-05-22
Inventor： Santanu Bose , Philippe Tessier
IPC: C07K16/24
CPC classification number: C07K16/24 , A61K2039/505 , C07K2317/76
Abstract: The present disclosure provides methods of treating a pathogen-induced lung inflammation in a subject are provided in which an anti-S100A9 antibody is administered to a subject. Methods of treating a respiratory virus infection by administering an anti-S100A9 antibody are also provided.
-
Patent Agency Ranking
176.发明授权公开(公告)号：US10067134B2
公开(公告)日：2018-09-04
申请号：US15408886
申请日：2017-01-18
Inventor： Pomila Singh
IPC: G01N33/574
Abstract: Provided herein is a method for diagnosing/prognosing a metastatic cancer in a subject by measuring and detecting one or more of CS-ANXA2, DCAMKL, Lgr5 or CS-ANAX2 and DCAMKL or CS-ANXA2 and Lgr5 positive circulating tumor stem cells in the subject's blood or plasma. Also provided is a method for distinguishing the presence of early stage primary cancer from advanced stage metastatic cancer in the subject by measuring and detecting AnnexinA2, CS-ANXA2 and DCAMKL-1 or Lgr5 in the blood or plasma. In addition, there is provided a method for distinguishing the presence of benign, pre-cancerous tumorous growths or cancerous tumors in the subject by measuring and detecting AnnexinA2 and circulating tumor stem cells positive for CS-ANXA2 and DCAMKL or CS-ANXA2 and Lgr5 in the blood or plasma.
-
公开(公告)号：US10029094B2
公开(公告)日：2018-07-24
申请号：US14947797
申请日：2015-11-20
Inventor： Michael P. Kilgard , Robert L. Rennaker, II
Abstract: A method for treating neural deficits resulting from multiple sclerosis, involving assessing a subject's motor, sensory, cognitive, or emotional deficits caused by multiple sclerosis; selecting a rehabilitative task based said deficits; determining the subject's acceptable performance threshold for the rehabilitative task; and providing a paired training therapy. The paired training therapy comprises having the subject to perform a trial of the rehabilitative task; classifying the subject's performance on the trial as either acceptable or unacceptable, wherein an acceptable performance is performance at or above the subject's acceptable performance threshold, and an unacceptable performance is performance below the subject's acceptable performance threshold; and reinforcing acceptable performance by selectively stimulating the subject's vagus nerve after completion of the acceptable performance.
-
公开(公告)号：US20180180614A1
公开(公告)日：2018-06-28
申请号：US15561193
申请日：2016-03-25
Inventor： James E. CROWE, JR. , Andrew I. FLYAK , Alexander BUKREYEV , Philipp ILINYKH
IPC: G01N33/569 , A61K39/395 , A61K39/42 , C07K16/10 , G01N33/577 , G01N33/68
CPC classification number: G01N33/56983 , A61K39/395 , A61K39/42 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/10 , C07K2317/21 , C07K2317/33 , C07K2317/55 , C07K2317/76 , C07K2317/92 , G01N33/577 , G01N33/68 , G01N2333/08
Abstract: The present disclosure is directed to antibodies binding to and neutralizing ebolavirus and methods for use thereof. The present disclosure is directed to a method of detecting an ebolavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Table 2, or an antibody fragment thereof; and (b) detecting ebolavirus glycoprotein in said sample by binding of said antibody or antibody fragment to antigen in said sample. In still further embodiments, the present disclosure concerns immunodetection kits for use with the iminunodetection methods described above.
-
179.发明授权公开(公告)号：US09988612B2
公开(公告)日：2018-06-05
申请号：US15127617
申请日：2015-03-20
Inventor： Andrew D. Ellington , Adam J. Meyer
IPC: C12N9/12 , C12P19/34 , C12N15/115 , C12N15/11
CPC classification number: C12N9/1247 , C12N15/111 , C12N15/115 , C12N2310/141 , C12N2310/16 , C12N2320/51 , C12N2330/00 , C12N2330/51 , C12P19/34 , C12Y207/07006
Abstract: Disclosed are T7 RNA polymerase variants with enhanced transcriptional activity. T7 RNA polymerase variants are known which have the ability to incorporate modified ribonucleotides into growing RNA molecules. However, these variants have relatively low levels of transcriptional activity. Presented herein are mutations that increase the transcriptional activity of the variants with broad substrate range.
-
公开(公告)号：US09988271B2
公开(公告)日：2018-06-05
申请号：US14557080
申请日：2014-12-01
Inventor： Karen Lozano , Lee Daniel Cremar
IPC: D01D1/02 , D01D7/00 , D01D10/02 , D01D10/06 , D01F9/21 , D01F11/12 , D06M11/55 , C01B31/00 , D04H1/4242 , C01B32/05 , C01B32/15 , C01B32/354 , C01B32/342 , C01B32/30 , C01B32/312 , D01D5/18 , D01F9/14 , D01F11/06 , D04H1/72 , D01F6/14
CPC classification number: C01B32/05 , C01B32/15 , C01B32/30 , C01B32/312 , C01B32/342 , C01B32/354 , C01B32/382 , D01D5/18 , D01F6/14 , D01F9/14 , D01F11/06 , D04H1/4242 , D04H1/72 , Y10T442/60
Abstract: A method of producing carbon fiber, yarns, and nonwoven carbon fiber cloths, includes forming suitable polymeric precursor microfibers and/or nanofibers using a centrifugal spinning process and decomposing at least a portion of the polymeric precursor fibers to form carbon fibers. The decomposition may be accomplished by treating the polymeric precursor fibers with acid vapor from an aqueous acid solution at a temperature of less than 250° C.
-
-
-
-
-
-
-
-
-
Search Results
1244
records
(took 0.048 seconds)
